Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes 55:2357-2364, 2006
DOI: 10.2337/db06-0116
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kahn, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kahn, S. E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Steven E. Kahn1, Bernard Zinman2, Steven M. Haffner3, M. Colleen O’Neill4, Barbara G. Kravitz4, Dahong Yu4, Martin I. Freed4, William H. Herman5, Rury R. Holman6, Nigel P. Jones4, John M. Lachin7, Giancarlo C. Viberti8, and the ADOPT Study Group*

1 Division of Metabolism, Endocrinology and Nutrition, Department of Internal Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington
2 Samuel Lunenfeld Research Institute, Mount Sinai Hospital and University of Toronto, Ontario, Canada
3 University of Texas Health Science Center at San Antonio, San Antonio, Texas
4 GlaxoSmithKline, King of Prussia, Pennsylvania
5 Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, Michigan
6 Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, U.K
7 Biostatistics Center, George Washington University, Rockville, Maryland
8 King’s College London School of Medicine, King’s College London, London, U.K

Address correspondence and reprint requests to Steven E. Kahn, MB, ChB, VA Puget Sound Health Care System (151), 1660 S. Columbian Way, Seattle, WA 98108. E-mail: skahn{at}u.washington.edu

Abbreviations: ADOPT, A Diabetes Outcome Progression Trial; CRP, C-reactive protein; CVD, cardiovascular disease; HOMA-IR, homeostasis model assessment of insulin resistance; PAI-1, plasminogen activator-1

The inflammatory factor C-reactive protein (CRP) and the fibrinolytic variables fibrinogen and plasminogen activator-1 (PAI-1) are associated with long-term cardiovascular morbidity. To determine the contribution of body adiposity (BMI), insulin sensitivity (homeostasis model assessment of insulin resistance [HOMA-IR], and glycemia (HbA1c [A1C]) to the levels of these inflammatory and fibrinolytic variables in recently diagnosed (≤3 years), drug-naive, type 2 diabetic subjects (fasting plasma glucose ≤10 mmol/l), we examined a representative subgroup (n = 921) of the U.S. cohort in ADOPT (A Diabetes Outcome Progression Trial). The relationship between levels of CRP, fibrinogen, PAI-1 antigen and PAI-1 activity, and baseline variables including National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome phenotype were explored. All four factors increased significantly with increasing numbers of metabolic syndrome components (P = 0.0136 to P < 0.0001). BMI (P < 0.0001) and HOMA-IR (P < 0.0001) but not A1C (P = 0.65) increased with increasing numbers of metabolic syndrome components. Adjustment of CRP levels for BMI eliminated the association between CRP and the number of metabolic syndrome components, while adjusting for HOMA-IR did not (P = 0.0028). The relationships of PAI-1 antigen and PAI-1 activity with the number of metabolic syndrome components were maintained after adjusting for BMI (P = 0.0002 and P = <0.0001, respectively) or HOMA-IR (P = 0.0008 and P = <0.0001, respectively), whereas that with fibrinogen was eliminated after adjusting for BMI but not after adjusting for HOMA-IR (P = 0.013). Adjustment for A1C had no effect on any of the relationships between the inflammatory and fibrinolytic factors and the metabolic syndrome. We conclude that in recently diagnosed, drug-naive type 2 diabetic subjects, markers of inflammation and fibrinolysis are strongly related to the number of metabolic syndrome components. Further, for CRP and fibrinogen this relationship is determined by body adiposity and not by insulin sensitivity or glucose control.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
C. Lorenzo, M. Serrano-Rios, M. T. Martinez-Larrad, C. Gonzalez-Villalpando, J. L. Gonzalez-Sanchez, M. J. Martinez-Calatrava, R. Gabriel, and S. M. Haffner
Is Waist Circumference an Essential Component of the Metabolic Syndrome?
Diabetes Care, August 1, 2007; 30(8): 2141 - 2142.
[Full Text] [PDF]


Home page
Diabetes CareHome page
A. G. Niehoff, T. W. van Haeften, N. C. Onland-Moret, C. C. Elbers, C. Wijmenga, and Y. T. van der Schouw
C-Reactive Protein Is Independently Associated With Glucose but Not With Insulin Resistance in Healthy Men
Diabetes Care, June 1, 2007; 30(6): 1627 - 1629.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao
Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome
J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1619 - 1624.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.